RadioMedix, Inc. is a clinical stage biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company is commercializing radiopharmaceuticals for PET imaging and therapeutic (alpha and beta-labeled) radiopharmaceuticals. RadioMedix has also established contract service facilities for academic and industrial partners: Full cGMP manufacturing and analytical suites for human clinical trials, and commercial phase manufacturing of the radiopharmaceuticals, in addition to small animal Molecular Imaging Center for the pre-clinical evaluation of new targets in vitro and in vivo.

From Bench To Bedside

RadioMedix offers a multitude of services. Our bench to bedside capabilities includes drug candidate selection, optimization of the drug formulation, evaluation of in vitro and in vivo studies in relevant disease models and a multitude of other preclinical services.



PRE CLINICAL

• Radiochemistry & Preclinical In Vitro Screening 

• In Vivo Toxicity, Efficacy, & Dosimetry in mice 

• Micro PET Imaging

CLINICAL & INVESTIGATIONAL

•Clinical trial designs & IND Filing 

• Alpha/Beta Emitter Radiolabeling

• On-Site Clinical Center



COMMERCIAL SCALE MANUFACTURING

•24,500 SQF Manufacturing & QC Facility

• Six Aseptic Clean Rooms 

• 21 CFR 211 Compliant

•NDA Enabling & Commercialization Scale Up









RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy
  RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy platform and diagnostic...
Radiomedix and Orano Med Announce the Initiation of the Phase II Multi-Center Clinical Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers
Houston, TX and Plano, TX, Jan. 03, 2022 (GLOBE NEWSWIRE) -- RadioMedix and Orano Med are pleased to announce the...
RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY
RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Phase Direct to Phase...

JOIN US VIRTUALLY 

00Days
00Hours
00Minutes
00Seconds